(Reuters) -German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 ...

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company ...

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key data updates expected in 2025.

"We expect 2025 to be a data-rich year with multiple important updates from our priority programs," said Chief Executive Ugur Sahin. BioNTech forecast revenue between 1.7 billion euros and 2.2 billion ...

Reports Q4 revenue EUR 1.19B vs. EUR 1.48B last year. “From the very beginning, BioNTech’s (BNTX) vision has been to translate our science into ...

The full audited consolidated financial statements as of and for the year ended December 31, 2024, can be found in BioNTech's Annual Report on Form 20-F filed today with the United States Securities ...

Freshfields has won a Düsseldorf regional court patent dispute on behalf of client Moderna against German COVID-19 vaccine ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

S&P Dow Jones uses “float” – the value of shares that aren’t held by insiders and that therefore trade frequently and are ...

As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...

Wildfire smoke exposure acutely increased IL-13 expression in NK cells and was negatively associated with COVID-19 vaccine immunity.